|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:atccode
|
P01 C B01
|
|
gptkbp:bioavailability
|
not well absorbed orally
|
|
gptkbp:brand
|
gptkb:Pentacarinat
gptkb:Pentamidine
|
|
gptkbp:casnumber
|
123-99-9
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C23 H34 N4 O10 S
|
|
gptkbp:class
|
imidazole derivative
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:composed_by
|
gptkb:chemical_compound
reaction of pentamidine with isethionic acid
|
|
gptkbp:contraindication
|
renal impairment
hypersensitivity to pentamidine
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
1940s
|
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:healthcare
|
gptkb:1959
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pentamidine isethionate
|
|
gptkbp:indication
|
gptkb:African_sleeping_sickness
gptkb:cutaneous_leishmaniasis
|
|
gptkbp:interacts_with
|
gptkb:diabetes
nephrotoxic drugs
antihypertensive agents
|
|
gptkbp:is_tested_for
|
conducted
|
|
gptkbp:lifespan
|
6-12 hours
|
|
gptkbp:mass
|
500.61 g/mol
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:p_hlevel
|
7.5
|
|
gptkbp:research_areas
|
infectious diseases
tropical medicine
|
|
gptkbp:route_of_administration
|
intravenous
intramuscular
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
hypoglycemia
hypotension
nephrotoxicity
pancreatitis
|
|
gptkbp:structure
|
contains a nitrogen atom
contains a branched alkyl chain
contains a pentamidine core
contains a sulfonate group
|
|
gptkbp:used_for
|
treatment of leishmaniasis
treatment of pneumonia caused by Pneumocystis jirovecii
|
|
gptkbp:whoessential_medicines_list
|
included
|
|
gptkbp:bfsParent
|
gptkb:pentamidine
|
|
gptkbp:bfsLayer
|
6
|